 |
 |
 |
 |
 |
 |
 |
- June 3, 2009 - Eyegate Pharma Announces that EGP-437 Improved Signs and Symptoms of Dry Eye Syndrome in a Phase II Study
- March 2, 2009 - EyeGate Pharma Completes Phase II Clinical Trial of EGP-437 for Treating Dry Eye Syndrome
- January 9, 2009 - EyeGate Pharma Receives Orphan Drug Designation for Corneal Graft Rejection from the U.S. FDA